Role of dendritic cells in the initiation, progress and modulation of systemic autoimmune diseases

Autoimmunity Reviews

Volumn 14, Issue 2, 2015, Pages 127-139

  Mackern Oberti, Juan Pablo ^a   Llanos, Carolina ^b   Vega, Fabián ^b   Salazar Onfray, Flavio ^c   Riedel, Claudia A ^a,d   Bueno, Susan M ^a,d   Kalergis, Alexis M ^a,b,d  

^a Pontificia Universidad Católica de Chile   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

^d INSERM   (France)

Author keywords

Dendritic cells; Immune tolerance; Immunotherapy; Lupus; Systemic autoimmunity

Indexed keywords

TOLL LIKE RECEPTOR; AUTOANTIGEN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; TOLL-LIKE RECEPTORS;

EID: 84921876503     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.10.010     Document Type: Review

References (216)

1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
2. Gratz I.K., Rosenblum M.D., Maurano M.M., Paw J.S., Truong H.A., Marshak-Rothstein A., et al. Cutting edge: self-antigen controls the balance between effector and regulatory T cells in peripheral tissues. J Immunol 2014, 192:1351-1355.
3. Luo X., Yang W., Ye D.-Q., Cui H., Zhang Y., Hirankarn N., et al. A functional variant in MicroRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet 2011, 7:e1002128.
4. Perez V.L., Van Parijs L., Biuckians A., Zheng X.X., Strom T.B., Abbas A.K. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997, 6:411-417.
5. Schreiner B., Bailey S.L., Shin T., Chen L., Miller S.D. PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE. Eur J Immunol 2008, 38:2706-2717.
6. Gianchecchi E., Delfino D.V., Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev 2013, 12:1091-1100.
7. Mok C., Ho L., To C. Annual incidence and standardized incidence ratio of cerebrovascular accidents in patients with systemic lupus erythematosus. Scand J Rheumatol 2009, 38:362-368.
8. Bernatsky S., Boivin J.F., Joseph L., Manzi S., Ginzler E., Gladman D.D., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54:2550-2557.
9. Carreño L.J., Pacheco R., Gutierrez M.A., Jacobelli S., Kalergis A.M. Disease activity in systemic lupus erythematosus is associated with an altered expression of low-affinity Fcγ receptors and costimulatory molecules on dendritic cells. Immunology 2009, 128:334-341.
10. Crispin J.C., Kyttaris V.C., Terhorst C., Tsokos G.C. T cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6:317-325.
11. Gaipl U.S., Munoz L.E., Grossmayer G., Lauber K., Franz S., Sarter K., et al. Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun 2007, 28:114-121.
12. Schwarz E., Ritchlin C. Clinical development of anti-RANKL therapy. Arthritis Res Ther 2007, 9:S7.
13. Houssiau F., Ginzler E. Current treatment of lupus nephritis. Lupus 2008, 17:426-430.
14. Hahn B.H. Belimumab for systemic lupus erythematosus. N Engl J Med 2013, 368:1528-1535.
15. Lee J.-H., Kim T.-H., Park H.E., Lee E.G., Jung N.-C., Song J.-Y., et al. Myosin-primed tolerogenic dendritic cells ameliorate experimental autoimmune myocarditis. Cardiovasc Res 2014, 101:203-210.
16. Mukhopadhaya A., Hanafusa T., Jarchum I., Chen Y.-G., Iwai Y., Serreze D.V., et al. Selective delivery of β cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proc Natl Acad Sci 2008, 105:6374-6379.
17. Van Brussel I., Lee W.P., Rombouts M., Nuyts A.H., Heylen M., De Winter B.Y., et al. Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality?. Autoimmun Rev 2014, 13:138-150.
18. Dufait I., Liechtenstein T., Lanna A., Bricogne C., Laranga R., Padella A., et al. Retroviral and lentiviral vectors for the induction of immunological tolerance. Scientifica 2012, 2012:14.
19. O'Neill L.A.J. Toll-like receptor signal transduction and the tailoring of innate immunity: a role for Mal?. Trends Immunol 2002, 23:296-300.
20. Ioannou S., Voulgarelis M. Toll-like receptors, tissue injury, and tumourigenesis. Mediators Inflamm 2010, 2010. [pp.].
21. Blasius A.L., Beutler B. Intracellular Toll-like receptors. Immunity 2010, 32:305-315.
22. Bueno S.M., Riedel C.A., Carreno L.J., Kalergis A.M. Virulence mechanisms displayed by Salmonella to impair dendritic cell function. Curr Med Chem 2010, 17:1156-1166.
23. Iruretagoyena M.I., Wiesendanger M., Kalergis A.M. The dendritic cell-T cell synapse as a determinant of autoimmune pathogenesis. Curr Pharm Des 2006, 12:131-147.
24. Kalergis A.M. Modulation of T cell immunity by TCR/pMHC dwell time and activating/inhibitory receptor pairs on the antigen-presenting cell. Curr Pharm Des 2003, 9:233-244.
25. Llanos C., Carreno L.J., Gutierrez M.A., Riedel C.A., Jacobelli S.H., Kalergis A.M. Genetic and pharmacological modulation of dendritic cell-T cell interactions as a therapeutic strategy for systemic lupus erythematosus. Curr Gene Ther 2011, 11. [pp.].
26. Diebold S.S. Determination of T-cell fate by dendritic cells. Immunol Cell Biol 2008, 86:389-397.
27. Brain O., Owens Benjamin M.J., Pichulik T., Allan P., Khatamzas E., Leslie A., et al. The intracellular sensor NOD2 induces microRNA-29 expression in human dendritic cells to limit IL-23 release. Immunity 2013, 39:521-536.
28. Ferwerda G., Kramer M., de Jong D., Piccini A., Joosten L.A., DevesaGiner I., et al. Engagement of NOD2 has a dual effect on proIL-1β mRNA transcription and secretion of bioactive IL-1β. Eur J Immunol 2008, 38:184-191.
29. Brosbøl-Ravnborg A., Hvas C.L., Agnholt J., Dahlerup J.F., Vind I., Till A., et al. Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways. Clin Exp Immunol 2009, 155:487-495.
30. Piccinini A.M., Midwood K.S. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010, 2010. [pp.].
31. Wen Z., Xu L., Chen X., Xu W., Yin Z., Gao X., et al. Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway. J Immunol 2013, 190:5411-5422.
32. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002, 416:603-607.
33. Doring Y., Manthey H.D., Drechsler M., Lievens D., Megens R.T., Soehnlein O., et al. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation 2012, 125:1673-1683.
34. Sandgren S., Wittrup A., Cheng F., Jonsson M., Eklund E., Busch S., et al. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J Biol Chem 2004, 279:17951-17956.
35. Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y.H., Homey B., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449:564-569.
36. Ganguly D., Chamilos G., Lande R., Gregorio J., Meller S., Facchinetti V., et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009, 206:1983-1994.
37. Dombrowski Y., Schauber J. Cathelicidin LL-37: a defense molecule with a potential role in psoriasis pathogenesis. Exp Dermatol 2012, 21:327-330.
38. Gilliet M., Lande R. Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol 2008, 20:401-407.
39. Bondanza A., Zimmermann V.S., Dell'Antonio G., Dal Cin E., Capobianco A., Sabbadini M.G., et al. Cutting edge: dissociation between autoimmune response and clinical disease after vaccination with dendritic cells. J Immunol 2003, 170:24-27.
40. Ma L., Chan K.W., Trendell-Smith N.J., Wu A., Tian L., Lam A.C., et al. Systemic autoimmune disease induced by dendritic cells that have captured necrotic but not apoptotic cells in susceptible mouse strains. Eur J Immunol 2005, 35:3364-3375.
41. Georgiev M., Agle L.M.A., Chu J.L., Elkon K.B., Ashany D. Mature dendritic cells readily break tolerance in normal mice but do not lead to disease expression. Arthritis Rheum 2005, 52:225-238.
42. Sacre K., Criswell L.A., McCune J.M. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 2012, 14:R155.
43. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69:20-28.
44. Means T.K., Latz E., Hayashi F., Murali M.R., Golenbock D.T., Luster A.D. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005, 115:407-417.
45. Clynes R., Dumitru C., Ravetch J.V. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998, 279:1052-1054.
46. Brown E.E., Edberg J.C., Kimberly R.P. Fc receptor genes and the systemic lupus erythematosus diathesis. Autoimmunity 2007, 40:567-581.
47. Nimmerjahn F., Ravetch J.V. Fc-receptors as regulators of immunity. Adv Immunol 2007, 96:179-204.
48. Nimmerjahn F., Bruhns P., Horiuchi K., Ravetch J.V. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005, 23:41-51.
49. Smith K.G., Clatworthy M.R. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010, 10:328-343.
50. Iruretagoyena M.I., Riedel C.A., Leiva E.D., Gutierrez M.A., Jacobelli S.H., Kalergis A.M. Activating and inhibitory Fcgamma receptors can differentially modulate T cell-mediated autoimmunity. Eur J Immunol 2008, 38:2241-2250.
51. Ravetch J.V., Bolland S. IgG Fc receptors. Annu Rev Immunol 2001, 19:275-290.
52. Herrada A.A., Contreras F.J., Tobar J.A., Pacheco R., Kalergis A.M. Immune complex-induced enhancement of bacterial antigen presentation requires Fcgamma receptor III expression on dendritic cells. Proc Natl Acad Sci U S A 2007, 104:13402-13407.
53. Kalergis A.M., Ravetch J.V. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002, 195:1653-1659.
54. Yuasa T., Kubo S., Yoshino T., Ujike A., Matsumura K., Ono M., et al. Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med 1999, 189:187-194.
55. Bolland S., Ravetch J.V. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 2000, 13:277-285.
56. Carreno L.J., Pacheco R., Gutierrez M.A., Jacobelli S., Kalergis A.M. Disease activity in systemic lupus erythematosus is associated with an altered expression of low-affinity Fc gamma receptors and costimulatory molecules on dendritic cells. Immunology 2009, 128:334-341.
57. Bave U., Magnusson M., Eloranta M.L., Perers A., Alm G.V., Ronnblom L. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 2003, 171:3296-3302.
58. Lovgren T., Eloranta M.L., Kastner B., Wahren-Herlenius M., Alm G.V., Ronnblom L. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum 2006, 54:1917-1927.
59. Mold C., Clos T.W.D. C-reactive protein inhibits plasmacytoid dendritic cell interferon responses to autoantibody immune complexes. Arthritis Rheum 2013, 65:1891-1901.
60. Tobar J.A., Gonzalez P.A., Kalergis A.M. Salmonella escape from antigen presentation can be overcome by targeting bacteria to Fc gamma receptors on dendritic cells. J Immunol 2004, 173:4058-4065.
61. Herrada A.A., Contreras F.J., Tobar J.A., Pacheco R., Kalergis A.M. Immune complex-induced enhancement of bacterial antigen presentation requires Fcγ receptor III expression on dendritic cells. Proc Natl Acad Sci 2007, 104:13402-13407.
62. Brownlie R.J., Lawlor K.E., Niederer H.A., Cutler A.J., Xiang Z., Clatworthy M.R., et al. Distinct cell-specific control of autoimmunity and infection by FcγRIIb. J Exp Med 2008, 205:883-895.
63. Bhardwaj N., Young J.W., Nisanian A.J., Baggers J., Steinman R.M. Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T cell responses. J Exp Med 1993, 178:633-642.
64. Beckman E.M., Porcelli S.A., Morita C.T., Behar S.M., Furlong S.T., Brenner M.B. Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. Nature 1994, 372:691-694.
65. Montamat-Sicotte D.J., Millington K.A., Willcox C.R., Hingley-Wilson S., Hackforth S., Innes J., et al. A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection. J Clin Invest 2011, 121:2493-2503.
66. Carreno L.J., Gonzalez P.A., Kalergis A.M. Modulation of T cell function by TCR/pMHC binding kinetics. Immunobiology 2006, 211:47-64.
67. Linsley P.S., Brady W., Grosmaire L., Aruffo A., Damle N.K., Ledbetter J.A. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991, 173:721-730.
68. Hubo M., Trinschek B., Kryczanowsky F., Tüttenberg A., Steinbrink K., Jonuleit H. Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front Immunol 2013, 4. [pp.].
69. Romo-Tena J., Gómez-Martín D., Alcocer-Varela J. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev 2013, 12:1171-1176.
70. Schneider H., Downey J., Smith A., Zinselmeyer B.H., Rush C., Brewer J.M., et al. Reversal of the TCR stop signal by CTLA-4. Science 2006, 313:1972-1975.
71. Grewal I.S., Foellmer H.G., Grewal K.D., Xu J., Hardardottir F., Baron J.L., et al. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 1996, 273:1864-1867.
72. Gerritse K., Laman J.D., Noelle R.J., Aruffo A., Ledbetter J.A., Boersma W.J., et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci 1996, 93:2499-2504.
73. Bagenstose L.M., Agarwal R.K., Silver P.B., Harlan D.M., Hoffmann S.C., Kampen R.L., et al. Disruption of CD40/CD40-ligand interactions in a retinal autoimmunity model results in protection without tolerance. J Immunol 2005, 175:124-130.
74. Crispin J.C., Vargas-Rojas M.I., Monsivais-Urenda A., Alcocer-Varela J. Phenotype and function of dendritic cells of patients with systemic lupus erythematosus. Clin Immunol 2012, 143:45-50.
75. Burgess J.K., Carlin S., Pack R.A., Arndt G.M., Au W.W., Johnson P.R.A., et al. Detection and characterization of OX40 ligand expression in human airway smooth muscle cells: a possible role in asthma?. J Allergy Clin Immunol 2004, 113:683-689.
76. Ito T., Wang Y.-H., Duramad O., Hori T., Delespesse G.J., Watanabe N., et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 2005, 202:1213-1223.
77. Gaspal F.M., Withers D., Saini M., Bekiaris V., McConnell F.M., White A., et al. Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice. J Exp Med 2011, 208:1579-1584.
78. Yoshinaga S.K., Whoriskey J.S., Khare S.D., Sarmiento U., Guo J., Horan T., et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999, 402:827-832.
79. Kopf M., Coyle A.J., Schmitz N., Barner M., Oxenius A., Gallimore A., et al. Inducible costimulator protein (Icos) controls T helper cell subset polarization after virus and parasite infection. J Exp Med 2000, 192:53-62.
80. Witsch E.J., Peiser M., Hutloff A., Büchner K., Dorner B.G., Jonuleit H., et al. ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells. Eur J Immunol 2002, 32:2680-2686.
81. Sim G.C., Martin-Orozco N., Jin L., Yang Y., Wu S., Washington E., et al. IL-2 therapy promotes suppressive ICOS+Treg expansion in melanoma patients. J Clin Invest 2014, 124:99-110.
82. Gao X., Zhao L., Wang S., Yang J., Yang X. Enhanced inducible costimulator ligand (ICOS-L) expression on dendritic cells in interleukin-10 deficiency and its impact on T-cell subsets in respiratory tract infection. Mol Med 2013, 19:346-356.
83. Mak T.W., Shahinian A., Yoshinaga S.K., Wakeham A., Boucher L.-M., Pintilie M., et al. Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cell-dependent B cell responses. Nat Immunol 2003, 4:765-772.
84. Ramos M.I., Tak P.P., Lebre M.C. Fms-like tyrosine kinase 3 ligand-dependent dendritic cells in autoimmune inflammation. Autoimmun Rev 2014, 13:117-124.
85. McKenna H.J., Stocking K.L., Miller R.E., Brasel K., De Smedt T., Maraskovsky E., et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000, 95:3489-3497.
86. Dehlin M., Bokarewa M., Rottapel R., Foster S.J., Magnusson M., Dahlberg L.E., et al. Intra-articular Fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis. PLoS One 2008, 3:e3633.
87. Erlandsson M.C., Forslind K., Andersson S.E.M., Lund A., Bokarewa M.I. Metastasin S100A4 is increased in proportion to radiographic damage in patients with RA. Rheumatology 2012, 51:932-940.
88. Yogev N., Frommer F., Lukas D., Kautz-Neu K., Karram K., Ielo D., et al. Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor+regulatory T cells. Immunity 2012, 37:264-275.
89. Yamazaki T., Akiba H., Iwai H., Matsuda H., Aoki M., Tanno Y., et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002, 169:5538-5545.
90. Zhong X., Tumang J.R., Gao W., Bai C., Rothstein T.L. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for VH11/VH12 and phosphatidylcholine binding. Eur J Immunol 2007, 37:2405-2410.
91. Keir M.E., Francisco L.M., Sharpe A.H. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 2007, 19:309-314.
92. Dilek N., Poirier N., Hulin P., Coulon F., Mary C., Ville S., et al. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells. PLoS One 2013, 8:e83139.
93. Francisco L.M., Salinas V.H., Brown K.E., Vanguri V.K., Freeman G.J., Kuchroo V.K., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009, 206:3015-3029.
94. Latchman Y.E., Liang S.C., Wu Y., Chernova T., Sobel R.A., Klemm M., et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A 2004, 101:10691-10696.
95. Nishimura H., Nose M., Hiai H., Minato N., Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151.
96. Chiba S., Baghdadi M., Akiba H., Yoshiyama H., Kinoshita I., Dosaka-Akita H., et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012, 13:832-842.
97. Maurya N., Gujar R., Gupta M., Yadav V., Verma S., Sen P. Immunoregulation of dendritic cells by the receptor T cell Ig and mucin protein-3 via Bruton's tyrosine kinase and c-Src. J Immunol 2014, 193:3417-3425.
98. Berggren O., Hagberg N., Weber G., Alm G.V., Rönnblom L., Eloranta M.-L. B lymphocytes enhance interferon-α production by plasmacytoid dendritic cells. Arthritis Rheum 2012, 64:3409-3419.
99. Karni A., Abraham M., Monsonego A., Cai G., Freeman G.J., Hafler D., et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006, 177:4196-4202.
100. Tucci M., Calvani N., Richards H.B., Quatraro C., Silvestris F. The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis. Ann N Y Acad Sci 2005, 1051:421-432.
101. Decker P., Kotter I., Klein R., Berner B., Rammensee H.G. Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2006, 45:1087-1095.
102. Kaisho T. Pathogen sensors and chemokine receptors in dendritic cell subsets. Vaccine 2012, 30:7652-7657.
103. Jarrossay D., Napolitani G., Colonna M., Sallusto F., Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001, 31:3388-3393.
104. Krug A., Towarowski A., Britsch S., Rothenfusser S., Hornung V., Bals R., et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001, 31:3026-3037.
105. Yu C.F., Peng W.M., Oldenburg J., Hoch J., Bieber T., Limmer A., et al. Human plasmacytoid dendritic cells support Th17 cell effector function in response to TLR7 ligation. J Immunol 2010, 184:1159-1167.
106. Villadangos J.A., Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 2008, 29:352-361.
107. Boonstra A., Asselin-Paturel C., Gilliet M., Crain C., Trinchieri G., Liu Y.-J., et al. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential Toll-like receptor ligation. J Exp Med 2003, 197:101-109.
108. Shortman K., Liu Y.-J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002, 2:151-161.
109. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005, 23:275-306.
110. Kuwana M., Kaburaki J., Wright T.M., Kawakami Y., Ikeda Y. Induction of antigen-specific human CD4+ T cell anergy by peripheral blood DC2 precursors. Eur J Immunol 2001, 31:2547-2557.
111. Izaguirre A., Barnes B.J., Amrute S., Yeow W.S., Megjugorac N., Dai J., et al. Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J Leukoc Biol 2003, 74:1125-1138.
112. Ito T., Kanzler H., Duramad O., Cao W., Liu Y.J. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood 2006, 107:2423-2431.
113. Jego G., Palucka A.K., Blanck J.-P., Chalouni C., Pascual V., Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19:225-234.
114. Cerutti A., Qiao X., He B. Plasmacytoid dendritic cells and the regulation of immunoglobulin heavy chain class switching. Immunol Cell Biol 2005, 83:554-562.
115. Poeck H., Wagner M., Battiany J., Rothenfusser S., Wellisch D., Hornung V., et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 2004, 103:3058-3064.
116. Ronnblom L.E., Alm G.V., Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 1991, 30:537-540.
117. Wilson L.E., Widman D., Dikman S.H., Gorevic P.D. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 2002, 32:163-173.
118. Kalkner K.M., Ronnblom L., Karlsson Parra A.K., Bengtsson M., Olsson Y., Oberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998, 91:393-399.
119. Maldonado-Lopez R., De Smedt T., Pajak B., Heirman C., Thielemans K., Leo O., et al. Role of CD8alpha+ and CD8alpha-dendritic cells in the induction of primary immune responses in vivo. J Leukoc Biol 1999, 66:242-246.
120. Kim S.J., Zou Y.R., Goldstein J., Reizis B., Diamond B. Tolerogenic function of Blimp-1 in dendritic cells. J Exp Med 2011, 208:2193-2199.
121. Han J.-W., Zheng H.-F., Cui Y., Sun L.-D., Ye D.-Q., Hu Z., et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 2009, 41:1234-1237.
122. Parlato S., Bruni R., Fragapane P., Salerno D., Marcantonio C., Borghi P., et al. IFN-α regulates Blimp-1 expression via miR-23a and miR-125b in both monocytes-derived DC and pDC. PLoS One 2013, 8:e72833.
123. Chen D.Y., Chen Y.M., Wen M.C., Hsieh T.Y., Hung W.T., Lan J.L. The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus 2012, 21:1385-1396.
124. Rana A., Minz R.W., Aggarwal R., Anand S., Pasricha N., Singh S. Gene expression of cytokines (TNF-alpha, IFN-gamma), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus 2012, 21:1105-1112.
125. Wong C.K., Lit L.C., Tam L.S., Li E.K., Wong P.T., Lam C.W. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008, 127:385-393.
126. Pan W.C., Chen R.M., Shen Y.C., Chen C.C., Ueng Y.F. Suppressive effect of tobacco smoke extracts on oral P-glycoprotein function and its impact in smoke-induced insult to oral epidermal cells. Toxicol Lett 2009, 185:116-123.
127. Xu L., Wang C., Zhou Y., Ren T., Wen Z. CpG oligonucleotides induce the differentiation of CD4+ Th17 cells by triggering plasmacytoid dendritic cells in adoptively cell transfer immunotherapy. Immunol Lett 2012, 142:55-63.
128. Ouabed A., Hubert F.X., Chabannes D., Gautreau L., Heslan M., Josien R. Differential control of T regulatory cell proliferation and suppressive activity by mature plasmacytoid versus conventional spleen dendritic cells. J Immunol 2008, 180:5862-5870.
129. Bonnefoy F., Couturier M., Clauzon A., Rémy-Martin J.-P., Gaugler B., Tiberghien P., et al. TGF-β-exposed plasmacytoid dendritic cells participate in Th17 commitment. J Immunol 2011, 186:6157-6164.
130. Fagarasan S., Honjo T. T-Independent immune response: new aspects of B cell biology. Science 2000, 290:89-92.
131. Gregersen J.W., Jayne D.R.W. B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol 2012, 8:505-514.
132. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985, 314:537-539.
133. Batista F.D., Harwood N.E. The who, how and where of antigen presentation to B cells. Nat Rev Immunol 2009, 9:15-27.
134. Tian J., Zekzer D., Hanssen L., Lu Y., Olcott A., Kaufman D.L. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol 2001, 167:1081-1089.
135. Blair P.A., Norena L.Y., Flores-Borja F., Rawlings D.J., Isenberg D.A., Ehrenstein M.R., et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010, 32:129-140.
136. + T cells and secrete interleukin-10. PLoS One 2013, 8:e70131.
137. Fayette J., Dubois B., Vandenabeele S., Bridon J.-M., Vanbervliet B., Durand I., et al. Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2. J Exp Med 1997, 185:1909-1918.
138. Wan S., Zhou Z., Duan B., Morel L. Direct B cell stimulation by dendritic cells in a mouse model of lupus. Arthritis Rheum 2008, 58:1741-1750.
139. Shaw J., Wang Y.H., Ito T., Arima K., Liu Y.J. Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70. Blood 2010, 115:3051-3057.
140. Litinskiy M.B., Nardelli B., Hilbert D.M., He B., Schaffer A., Casali P., et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002, 3:822-829.
141. Hua Z., Gross A.J., Lamagna C., Ramos-Hernández N., Scapini P., Ji M., et al. Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice. J Immunol 2014, 192:875-885.
142. Teichmann L.L., Ols M.L., Kashgarian M., Reizis B., Kaplan D.H., Shlomchik M.J. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 2010, 33:967-978.
143. Qian L., Qian C., Chen Y., Bai Y., Bao Y., Lu L., et al. Regulatory dendritic cells program B cells to differentiate into CD19hiFcgammaIIbhi regulatory B cells through IFN-beta and CD40L. Blood 2012, 120:581-591.
144. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
145. Sakaguchi S., Ono M., Setoguchi R., Yagi H., Hori S., Fehervari Z., et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006, 212:8-27.
146. Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299:1033-1036.
147. Wan S., Xia C., Morel L. IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J Immunol 2007, 178:271-279.
148. McNally A., McNally M., Galea R., Thomas R., Steptoe R.J. Immunogenic, but not steady-state, antigen presentation permits regulatory T-cells to control CD8+ T-cell effector differentiation by IL-2 modulation. PLoS One 2014, 9:e85455.
149. Grondal G., Gunnarsson I., Ronnelid J., Rogberg S., Klareskog L., Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000, 18:565-570.
150. Dean G.S., Tyrrell-Price J., Crawley E., Isenberg D.A. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 2000, 59:243-251.
151. Amerio P., Frezzolini A., Abeni D., Teofoli P., Girardelli C.R., De Pita O., et al. Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin Exp Rheumatol 2002, 20:535-538.
152. Tackey E., Lipsky P.E., Illei G.G. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004, 13:339-343.
153. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711.
154. Guerder S., Joncker N., Mahiddine K., Serre L. Dendritic cells in tolerance and autoimmune diabetes. Curr Opin Immunol 2013, 25:670-675.
155. Raïch-Regué D., Glancy M., Thomson A.W. Regulatory dendritic cell therapy: From rodents to clinical application. Immunol Lett 2014, 161:216-221.
156. Llanos C., Mackern-Oberti J.P., Vega F., Jacobelli S.H., Kalergis A.M. Tolerogenic dendritic cells as a therapy for treating lupus. Clin Immunol 2013, 148:237-245.
157. Rea D., van Kooten C., van Meijgaarden K.E., Ottenhoff T.H., Melief C.J., Offringa R. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood 2000, 95:3162-3167.
158. Xing N., ML L.M., Bachman L.A., McKean D.J., Kumar R., Griffin M.D. Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways. Biochem Biophys Res Commun 2002, 297:645-652.
159. Moser M., De Smedt T., Sornasse T., Tielemans F., Chentoufi A.A., Muraille E., et al. Glucocorticoids down-regulate dendritic cell function in vitro and in vivo. Eur J Immunol 1995, 25:2818-2824.
160. Iruretagoyena M.I., Tobar J.A., Gonzalez P.A., Sepulveda S.E., Figueroa C.A., Burgos R.A., et al. Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. J Pharmacol Exp Ther 2005, 312:366-372.
161. Hackstein H., Morelli A.E., Larregina A.T., Ganster R.W., Papworth G.D., Logar A.J., et al. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol 2001, 166:7053-7062.
162. Hackstein H., Taner T., Logar A.J., Thomson A.W. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002, 100:1084-1087.
163. Hackstein H., Taner T., Zahorchak A.F., Morelli A.E., Logar A.J., Gessner A., et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003, 101:4457-4463.
164. Unger W.W.J., Laban S., Kleijwegt F.S., van der Slik A.R., Roep B.O. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol 2009, 39:3147-3159.
165. Leung D.Y.M., Bloom J.W. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2003, 111:3-22.
166. Ko H., Hambly B.D., Eris J.M., Levidiotis V., Wyburn K., Wu H., et al. Dentritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A, but not cyclosporine A. Transpl Immunol 2008, 20:99-105.
167. Simon T., Pogu S., Tardif V., Rigaud K., Rémy S., Piaggio E., et al. Carbon monoxide-treated dendritic cells decrease β1-integrin induction on CD8+ T cells and protect from type 1 diabetes. Eur J Immunol 2013, 43:209-218.
168. Chauveau C., Remy S., Royer P.J., Hill M., Tanguy-Royer S., Hubert F.X., et al. Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood 2005, 106:1694-1702.
169. Martin E., Capini C., Duggan E., Lutzky V.P., Stumbles P., Pettit A.R., et al. Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-κB. Arthritis Rheum 2007, 56:2255-2266.
170. Ding Y., Chen D., Tarcsafalvi A., Su R., Qin L., Bromberg J.S. Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. J Immunol 2003, 170:1383-1391.
171. Sato K., Nagayama H., Tadokoro K., Juji T., Takahashi T.A. Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk are involved in il-10-mediated selective repression of TNF-α-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J Immunol 1999, 162:3865-3872.
172. Knodler A., Schmidt S.M., Bringmann A., Weck M.M., Brauer K.M., Holderried T.A.W., et al. Post-transcriptional regulation of adapter molecules by IL-10 inhibits TLR-mediated activation of antigen-presenting cells. Leukemia 2008, 23:535-544.
173. Murray P.J. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr Opin Pharmacol 2006, 6:379-386.
174. Kubsch S., Graulich E., Knop J., Steinbrink K. Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2-and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1. Eur J Immunol 2003, 33:1988-1997.
175. Steinbrink K., Graulich E., Kubsch S., Knop J., Enk A.H. CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002, 99:2468-2476.
176. Li X., Yang A., Huang H., Zhang X., Town J., Davis B., et al. Induction of type 2 T helper cell allergen tolerance by IL-10-differentiated regulatory dendritic cells. Am J Respir Cell Mol Biol 2010, 42:190-199.
177. Velten F.W., Duperrier K., Bohlender J., Metharom P., Goerdt S. A gene signature of inhibitory MHC receptors identifies a BDCA3+ subset of IL-10-induced dendritic cells with reduced allostimulatory capacity in vitro. Eur J Immunol 2004, 34:2800-2811.
178. Lopez M.N., Pesce B., Kurte M., Perez C., Segal G., Roa J., et al. A synthetic peptide homologous to IL-10 functional domain induces monocyte differentiation to TGF-beta+ tolerogenic dendritic cells. Immunobiology 2011, 216:1117-1126.
179. Thomas D.C., Wong F.S., Zaccone P., Green E.A., Wållberg M. Protection of islet grafts through transforming growth factor-β-induced tolerogenic dendritic cells. Diabetes 2013, 62:3132-3142.
180. D'Ambrosio A., Colucci M., Pugliese O., Quintieri F., Boirivant M. Cholera toxin B subunit promotes the induction of regulatory T cells by preventing human dendritic cell maturation. J Leukoc Biol 2008, 84:661-668.
181. Carranza F., Falcon C.R., Nunez N., Knubel C., Correa S.G., Bianco I., et al. Helminth antigens enable CpG-activated dendritic cells to inhibit the symptoms of collagen-induced arthritis through Foxp3+ regulatory T cells. PLoS One 2012, 7:e40356.
182. Vukman K.V., Adams P.N., Metz M., Maurer M., O'Neill S.M. Fasciola hepatica tegumental coat impairs mast cells' ability to drive Th1 immune responses. J Immunol 2013, 190:2873-2879.
183. Pauley K., Cha S. RNAi therapeutics in autoimmune disease. Pharmaceuticals 2013, 6:287-294.
184. Apparailly F., Jorgensen C. siRNA-based therapeutic approaches for rheumatic diseases. Nat Rev Rheumatol 2013, 9:56-62.
185. Li R., Zheng X., Popov I., Zhang X., Wang H., Suzuki M., et al. Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. J Transl Med 2012, 10:19.
186. Zheng X., Suzuki M., Ichim T.E., Zhang X., Sun H., Zhu F., et al. Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol 2010, 184:6457-6464.
187. Zheng X., Suzuki M., Zhang X., Ichim T., Zhu F., Ling H., et al. RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Ther 2010, 12:R13.
188. Kalantari T., Karimi M.H., Ciric B., Yan Y., Rostami A., Kamali-Sarvestani E. Tolerogenic dendritic cells produced by Lentiviral-mediated CD40-and IL-23p19-specific shRNA can ameliorate experimental autoimmune encephalomyelitis by suppressing Th17 cells. Clin Exp Immunol 2014, 176:180-189.
189. Ferenbach D.A., Ramdas V., Spencer N., Marson L., Anegon I., Hughes J., et al. Macrophages expressing heme oxygenase-1 improve renal function in ischemia/reperfusion injury. Mol Ther 2010, 18:1706-1713.
190. Coleman M.A., Steptoe R.J. Induction of antigen-specific tolerance through hematopoietic stem cell-mediated gene therapy: the future for therapy of autoimmune disease?. Autoimmun Rev 2012, 12:195-203.
191. Mancardi G.L., Murialdo A., Rossi P., Gualandi F., Martino G., Marmont A., et al. Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Mult Scler 2005, 11:367-371.
192. Snowden J.A., Passweg J., Moore J.J., Milliken S., Cannell P., Van Laar J., et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol 2004, 31:482-488.
193. Burt R.K., Traynor A., Statkute L., Barr W.G., Rosa R., Schroeder J., et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006, 295:527-535.
194. Couri C.E., Oliveira M.C., Stracieri A.B., Moraes D.A., Pieroni F., Barros G.M., et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009, 301:1573-1579.
195. Chan J., Ban E.J., Chun K.H., Wang S., Bäckström B.T., Bernard C.C.A., et al. Transplantation of bone marrow transduced to express self-antigen establishes deletional tolerance and permanently remits autoimmune disease. J Immunol 2008, 181:7571-7580.
196. Steptoe R.J., Ritchie J.M., Harrison L.C. Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes. J Clin Invest 2003, 111:1357-1363.
197. Fritsch-Stork R., Mullegger D., Skriner K., Jahn-Schmid B., Smolen J., Steiner G. The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus. Arthritis Res Ther 2006, 8:R118.
198. Kalergis A.M., Iruretagoyena M.I., Barrientos M.J., Gonzalez P.A., Herrada A.A., Leiva E.D., et al. Modulation of nuclear factor-kappaB activity can influence the susceptibility to systemic lupus erythematosus. Immunology 2009, 128:e306-e314.
199. Kang H.K., Liu M., Datta S.K. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol 2007, 178:7849-7858.
200. Kang H.-K., Chiang M.-Y., Liu M., Ecklund D., Datta S. The histone peptide H471-94 alone is more effective than a cocktail of peptide epitopes in controlling lupus: immunoregulatory mechanisms. J Clin Immunol 2011, 31:379-394.
201. Sela U., Sharabi A., Dayan M., Hershkoviz R., Mozes E. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models. Immunology 2009, 128:e395-e405.
202. Sthoeger Z., Zinger H., Sharabi A., Asher I., Mozes E. The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-α in murine and human systemic lupus erythematosus. PLoS One 2013, 8:e60394.
203. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005, 353:2219-2228.
204. Singh J.A., Wells G.A., Christensen R., Tanjong Ghogomu E., Maxwell L., Macdonald J.K., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, 2. CD008794.
205. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
206. Beyaert R., Beaugerie L., Van Assche G., Brochez L., Renauld J.-C., Viguier M., et al. Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer 2013, 12:98.
207. Giannoukakis N., Phillips B., Finegold D., Harnaha J., Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011, 34:2026-2032.
208. Giannoukakis N. Interview: immunoregulatory dendritic cells to treat autoimmunity are ready for the clinic. Immunotherapy 2013, 5:919-921.
209. Raïch-Regué D., Grau-López L., Naranjo-Gómez M., Ramo-Tello C., Pujol-Borrell R., Martínez-Cáceres E., et al. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol 2012, 42:771-782.
210. Chiurchì V., Cencioni M.T., Bisicchia E., De Bardi M., Gasperini C., Borsellino G., et al. Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. Ann Neurol 2013, 73:626-636.
211. Gross C.C., Jonuleit H., Wiendl H. Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis. Eur J Immunol 2012, 42:569-572.
212. Thomas R., Ramnoruth N., Pahau H., Law S., Brunck M., et al. Feasibility, safety and clinical effects of Single intradermal administration of autologous tolerising dendritic cells exposed to citrullinated peptides in patients with rheumatoid arthritis. Arthritis Rheum 2011, 63:2430.
213. Doyle H.A., Mamula M.J. Autoantigenesis: the evolution of protein modifications in autoimmune disease. Curr Opin Immunol 2012, 24:112-118.
214. Rekvig O.P., Nossent J.C. Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms?. Arthritis Rheum 2003, 48:300-312.
215. Figueroa-Vega N., Galindo-Rodríguez G., Bajaña S., Portales-Pérez D., Abud-Mendoza C., Sánchez-Torres C., et al. Phenotypic analysis of IL-10-treated, monocyte-derived dendritic cells in patients with systemic lupus erythematosus. Scand J Immunol 2006, 64:668-676.
216. Carreno L.J., Riedel C.A., Kalergis A.M. Induction of tolerogenic dendritic cells by NF-kappaB blockade and Fcgamma receptor modulation. Methods Mol Biol 2010, 677:339-353.